Ventrus Biosciences (VTUS) 1.45 $VTUS
Ventrus Biosciences Becomes Assembly Biosciences as Stockholders Approve Merger With Assembly Pharmaceuticals, Inc.
GlobeNewswire - Mon Jul 14, 6:00AM CDT
Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced that its stockholders have approved the issuance of common stock in connection with the merger between Ventrus and Assembly Pharmaceuticals, Inc. in an all-stock transaction. The merger was effective at 5:00 p.m. ET on July 11, 2014.
VTUS: 1.45 (+0.01)
3 Stocks Under $10 Moving Higher
at The Street - Wed Jul 09, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
VTUS: 1.45 (+0.01), GPL: 0.64 (unch), MUX: 1.10 (+0.06)
Health Care Sector Stocks Coverage -- Research on RadNet, IMS Health Holdings, WuXi PharmaTech Cayman, and Ventrus Biosciences
PR Newswire - Wed Jun 18, 6:50AM CDT
On Tuesday, June 17, 2014, the NASDAQ Composite ended at 4,337.23, up 0.37%, the Dow Jones Industrial Average finished the day 0.16% higher at 16,808.49, and the S&P 500 closed at 1,941.99, up 0.22%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 688.85, down 0.07%, while the index has advanced 2.52% in the last one month. Investor-Edge has initiated coverage on the following equities: RadNet Inc. (NASDAQ: RDNT), IMS Health Holdings Inc. (NYSE: IMS), WuXi PharmaTech Cayman Inc. (NYSE: WX) and Ventrus Biosciences Inc. (NASDAQ: VTUS). Free technical research on RDNT, IMS, WX and VTUS can be downloaded upon signing up at:
VTUS: 1.45 (+0.01), IMS: 25.68 (+0.22), RDNT: 8.66 (-0.11), WX: 41.53 (+0.45)
Ventrus BioSciences Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon Jun 16, 6:00AM CDT
Ventrus BioSciences, Inc. (NASDAQ: VTUS) is a development-stage specialty pharmaceutical company currently focused on the development of gastrointestinal products, including infections of the gastrointestinal system. Out of the four product candidates the company has in-licensed, VTUS is actively developing only two of them right now. These candidates include VEN 307, a diltiazem cream for the relief of pain associated with anal fissures, and VEN 310 for use as a colonic delivery mechanism, which is a pH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules and other treatments to the gastrointestinal tract. In addition, VTUS intends to in-license or acquire other development stage and pre-clinical compounds and biologics.
VTUS: 1.45 (+0.01)
Ventrus Biosciences Becomes Assembly Biosciences as Stockholders Approve Merger With Assembly Pharmaceuticals, Inc.
GlobeNewswire - Mon Jul 14, 6:00AM CDT
Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced that its stockholders have approved the issuance of common stock in connection with the merger between Ventrus and Assembly Pharmaceuticals, Inc. in an all-stock transaction. The merger was effective at 5:00 p.m. ET on July 11, 2014.
VTUS: 1.45 (+0.01)
3 Stocks Under $10 Moving Higher
at The Street - Wed Jul 09, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
VTUS: 1.45 (+0.01), GPL: 0.64 (unch), MUX: 1.10 (+0.06)
Health Care Sector Stocks Coverage -- Research on RadNet, IMS Health Holdings, WuXi PharmaTech Cayman, and Ventrus Biosciences
PR Newswire - Wed Jun 18, 6:50AM CDT
On Tuesday, June 17, 2014, the NASDAQ Composite ended at 4,337.23, up 0.37%, the Dow Jones Industrial Average finished the day 0.16% higher at 16,808.49, and the S&P 500 closed at 1,941.99, up 0.22%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 688.85, down 0.07%, while the index has advanced 2.52% in the last one month. Investor-Edge has initiated coverage on the following equities: RadNet Inc. (NASDAQ: RDNT), IMS Health Holdings Inc. (NYSE: IMS), WuXi PharmaTech Cayman Inc. (NYSE: WX) and Ventrus Biosciences Inc. (NASDAQ: VTUS). Free technical research on RDNT, IMS, WX and VTUS can be downloaded upon signing up at:
VTUS: 1.45 (+0.01), IMS: 25.68 (+0.22), RDNT: 8.66 (-0.11), WX: 41.53 (+0.45)
Ventrus BioSciences Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon Jun 16, 6:00AM CDT
Ventrus BioSciences, Inc. (NASDAQ: VTUS) is a development-stage specialty pharmaceutical company currently focused on the development of gastrointestinal products, including infections of the gastrointestinal system. Out of the four product candidates the company has in-licensed, VTUS is actively developing only two of them right now. These candidates include VEN 307, a diltiazem cream for the relief of pain associated with anal fissures, and VEN 310 for use as a colonic delivery mechanism, which is a pH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules and other treatments to the gastrointestinal tract. In addition, VTUS intends to in-license or acquire other development stage and pre-clinical compounds and biologics.
VTUS: 1.45 (+0.01)
